Qelbree® viloxazine extended-release capsules

CO-PAY CARD PROGRAM

Commercially insured patients pay as little as $20 per prescription, each month, for a year.*

Removes majority of coverage obstacles for 30-day prescriptions.



Qelbree® viloxazine
extended-release capsules
100 mg 150 mg 200 mg

*Terms and Conditions: Offer void where prohibited. For full terms and conditions, please see the Qelbree Co-pay Card, or visit www.Qelbree.com.

Please see full Prescribing Information, including Boxed Warning and Important Safety Information on page 3.

Be sure patients activate the card to access savings

Follow Pharmacy Instructions if needed

Coverage Tip: Qelbree coverage is expanding to most major insurance plans. Some plans require a Prior Authorization. Please be sure to submit all required information for your patients.



Card not working? Call
1-855-725-7736

Qelbree®
viloxazine
extended-release capsules
100 mg 150 mg 200 mg

Please see full Prescribing Information, including Boxed Warning and Important Safety Information on page 3.

Issues at the Pharmacy?

Follow the instructions to help address common issues that you may encounter when processing the co-pay card for Qelbree.

General Instructions

If you receive a rejection due to a Managed Care Restriction (eg, Not Covered or NDC Block) and the pharmacy system allows, continue processing with valid OCC (Other Coverage Code) of "3."

Each pharmacy may have its own set of practice management systems and procedures, so these instructions may not apply. If the pharmacy still cannot adjudicate the claim, please call the McKesson Help Desk at **1-855-725-7736**.

Walgreens®, please use the following steps: (this rebate can be utilized for patients who are INSURED/NOT COVERED)

1) Enter in copay card BIN#, GROUP#, and ID# into the profile
2) Process through primary insurance to see if covered at all. If there is a rejection for "drug not covered," PA or step-edit, cash out the prescription and process an SDL (submit direct link)
3) Complete the SDL form, first processing for the primary insurance so that it will reflect the rejection from the primary payer
4) Once the SDL through the primary rejects, cash it out
5) Next, process the SDL for the rebate card using the OCC (Other Coverage Code) "3" (other coverage exists, this claim is not covered)

Walmart®, please use the following steps: (this rebate can be utilized for patients who are INSURED/NOT COVERED)

1) Adjudicate the claim through patient's primary insurance–it will reject
2) If claim requires PA, step-edit or is NDC blocked, bypass the rejection and run the claim as a secondary payer by either choosing "OCC" (Other Coverage Code) "3" or selecting "have insurance coverage, no payment collected"
3) Utilize the BIN#, GROUP#, and ID# located on the rebate

CVS Pharmacy®, please use the following steps: (this rebate can be utilized for patients who are INSURED/NOT COVERED)

1) Run the primary insurance with rebate as secondary. Enter BIN#, GROUP#, and ID# located on the rebate. After running the primary claim, a prompt will come up that says "Do you want to split the bill?" Select "Yes" and the next prompts to run the claim
2) The primary will reject and the secondary will show "Pending" status
3) In the reject message (DUR) screen, type in initials "BP" to bypass insurance or press the BP button in the lower right-hand corner of the screen (the OCC-3 claim will autopopulate when pharmacist enters "BP")
4) Once bypassed, the system will say "only proceed if claim is unresolvable." DO NOT edit any fields, submit claim and let the system autoprocess

Target®, please use the following steps: (this rebate can be utilized for patients who are INSURED/NOT COVERED)

1) Run the claim through the patient's primary insurance—it will reject
2) If the claim requires PA, step-edit, or is NDC blocked, submit OCC (Other Coverage Code) "3" **OR** Secondary Claim "8" using the rebate card. When submitting 3/8 claim, the pharmacy should click "YES" when prompted "transmit to other insurance." This does not always happen but is a good problem-solving technique if he/she runs into difficulty
3) Utilize the BIN#, GROUP#, and ID# located on the rebate

INDICATION

Qelbree is indicated for the treatment of ADHD in adults and pediatric patients 6 years and older.

IMPORTANT SAFETY INFORMATION

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

CONTRAINDICATIONS

- Concomitant administration of a monoamine oxidase inhibitor (MAOI), or dosing within 14 days after discontinuing an MAOI, because of an increased risk of hypertensive crisis
- Concomitant administration of sensitive CYP1A2 substrates or CYP1A2 substrates with a narrow therapeutic range

WARNINGS & PRECAUTIONS

- *Suicidal thoughts and behaviors*: Closely monitor all Qelbree-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy, and at times of dosage changes
- *Heart rate, blood pressure increases*: Qelbree can cause an increase in diastolic blood pressure and heart rate. Assess these measures prior to starting therapy, following increases in dosage, and periodically during therapy
- *Activation of mania or hypomania*: Noradrenergic drugs may induce a manic or mixed episode in patients with bipolar disorder. Prior to initiating treatment with Qelbree, screen patients to determine if they are at risk for bipolar disorder. Screening should include a detailed psychiatric history, including a personal or family history of suicide, bipolar disorder, and depression
- *Somnolence and fatigue*: Patients should not perform activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, due to potential somnolence (including sedation or lethargy) and fatigue, until they know how they will be affected by Qelbree

ADVERSE REACTIONS

The most common adverse reactions (≥5% and at least twice the rate of placebo for any dose) in patients 6 to 17 years were somnolence, decreased appetite, fatigue, nausea, vomiting, insomnia, and irritability, and in adults, insomnia, headache, somnolence, fatigue, nausea, decreased appetite, dry mouth, and constipation.

PREGNANCY

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Qelbree during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychiatric Medications at 1-866-961-2388 or by visiting www.womensmentalhealth.org/preg.

Please see full Prescribing Information, including Boxed Warning.

ONCE-DAILY Qelbree® viloxazine extended-release capsules 100 mg 150 mg 200 mg

Supernus® Pharmaceuticals

Qelbree is a registered trademark of Supernus Pharmaceuticals, Inc.
©2023 Supernus Pharmaceuticals, Inc. All rights reserved. QBE.2023-0042